Table of contents
December 2006 Vol 6 No 12
From the editors
p899 | doi:10.1038/nrc2045
Research Highlights
Tumorigenesis: Intricate insights
p901 | doi:10.1038/nrc2039
Tumour suppressors: Body building is about teamwork
p902 | doi:10.1038/nrc2038
Trial Watch
Stratifying risk in prostate and cervical cancer
p902 | doi:10.1038/nrc2043
Leukaemia stem cells: More frequent and more mature
p903 | doi:10.1038/nrc2034
Tumour suppressors: Expanding the pathway
p903 | doi:10.1038/nrc2035
Tumour stem cells: Rooting out resistance
p904 | doi:10.1038/nrc2031
Metastasis: Contract and move
p904 | doi:10.1038/nrc2032
In the news
Sugar caned
p904 | doi:10.1038/nrc2044
In brief
Cell death | Tumour suppression | Tumour development | Signalling
p905 | doi:10.1038/nrc2042
Tumour stem cells: Generating colon cancer
p906 | doi:10.1038/nrc2040
Tumour suppressors: It takes two to tango
p906 | doi:10.1038/nrc2041
Oncogenes: Polar architecture disrupted
p907 | doi:10.1038/nrc2033
Reviews
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Franck Toledo & Geoffrey M. Wahl
p909 | doi:10.1038/nrc2012
Understanding p53 regulation remains a crucial goal to design broadly applicable anticancer strategies that target this pathway. In this context, this Review analyses the function of p53 post-translational modifications and the p53 regulators MDM2 and MDM4 using recent in vitro and in vivo data.
Cancer as an evolutionary and ecological process
Lauren M.F. Merlo, John W. Pepper, Brian J. Reid & Carlo C. Maley
p924 | doi:10.1038/nrc2013
Neoplasms are microcosms of evolution. The evolution of neoplastic cells explains why we get cancer and why it has been so difficult to cure. Can evolutionary biology provide new insights into the clinical control of cancer?
Gastrin — active participant or bystander in gastric carcinogenesis?
Susan A. Watson, Anna M. Grabowska, Mohamad El-Zaatari & Arjun Takhar
p936 | doi:10.1038/nrc2014
The hormone gastrin has a central role in gastric acid secretion and is associated with malignant progression in transgenic mouse models. Does gastrin participate in human gastric cancers or is it merely a bystander?
The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis
Daniel W. Nebert & Timothy P. Dalton
p947 | doi:10.1038/nrc2015
Some cytochrome P450 (CYP) enzymes participate in the detoxication of xenobiotics and, paradoxically, can form reactive intermediates that can damage DNA, lipids and proteins. What function do these enzymes have in carcinogenesis driven by the environment?
Perspectives
Opinion
The blood peptidome: a higher dimension of information content for cancer biomarker discovery
Emanuel F. Petricoin, Claudio Belluco, Robyn P. Araujo & Lance A. Liotta
p961 | doi:10.1038/nrc2011
The peptidome is the range of low-molecular-weight peptides found in the bloodstream, and seems to differ between patients with and without cancer. How can the peptidome best be studied, and can it be used for cancer diagnostics?
Opinion
Cytoskeleton out of the cupboard: colon cancer and cytoskeletal changes induced by loss of APC
Inke Näthke
p967 | doi:10.1038/nrc2010
There is evidence that apart from its ability to regulate the transcriptional activity of 
-catenin, adenomatus polyposis coli (APC) has -catenin-independent functions. Is the interaction of APC with cytoskeletal components important for cancer development and progression in the gut?
Erratum: Integration of EGFR inhibitors with radiochemotherapy
Mukesh K. Nyati, Meredith A. Morgan, Felix Y. Feng & Theodore S. Lawrence
p974 | doi:10.1038/nrc2030